Highlights

  • Q2 FY26 sales revenue reached $6.48 million, according to the company’s January 2026 trading update.
  • H1 FY26 sales revenue reached $12.42 million, an increase of 40.2% on the corresponding period.
  • Biome entered an agreement in June 2026 to manufacture its Activated Probiotics range in Australia.
  • The proposed manufacturing transition is designed to reduce inventory and international freight requirements.
  • The company is developing its proprietary BMB18 probiotic strain through a multi-centre clinical programme.

Biome Australia Limited (ASX:BIO) develops, licenses, commercialises and markets evidence-based live biotherapeutics and complementary medicines, including its Activated Probiotics range. Its 2026 disclosures cover changes to probiotic manufacturing, sales across the first half of FY26, and a clinical programme involving a proprietary bacterial strain.

Half-Year Sales and the Pharmacy Channel

In a trading update dated 5 January 2026, Biome Australia (ASX:BIO) reported Q2 FY26 sales revenue of $6.48 million, a 40.9% increase on the previous corresponding period and 9.1% above Q1 FY26. The company reported H1 FY26 revenue of $12.42 million, representing growth of 40.2% on the corresponding half-year.

The update attributed the result to demand for its probiotic products. Sales were recorded during a quarter that the company described as seasonally affected by fewer December trading days and the pharmacy channel’s emphasis on gifting categories. Sales alone do not establish profitability.

Australian Manufacturing Agreement

On 3 June 2026, Biome Australia (ASX:BIO) announced a binding commercial agreement with Specialty Probiotics Australia to manufacture, test and package Activated Probiotics products domestically. The agreement does not require an upfront capital investment or minimum purchase commitment from Biome. Its initial term is two years, with regular review provisions.

Under the arrangement, Biome supplies active ingredients while the manufacturing partner undertakes Australian production and finishing. Biome Australia (ASX:BIO) indicated that the first commercial batch was targeted for September 2026, with the range expected to transition progressively over about 18 months, subject to commercial scale-up. The initial target is not confirmation that production began on that date.

The announcement identified reduced shipping requirements, shorter inventory cycles and faster stock turnover as intended benefits. Biome stated that its gross margin of approximately 61% could progressively move above 65% as local manufacturing is implemented. These figures were management expectations at the announcement date, not verified realised outcomes.

BMB18 Research Programme

Separately, Biome Australia (ASX:BIO) announced in May 2026 that recruitment had started at sites in Melbourne and Athens for a multi-centre study of BMB18, its proprietary Lactiplantibacillus plantarum strain. The company described preclinical work examining intestinal barrier function, immune modulation and antioxidant activity. Those mechanistic findings should not be confused with demonstrated clinical efficacy in patients.

The company also disclosed that a patent application covering the strain and its potential applications remained subject to examination. The clinical study and intellectual-property work represent a different activity from sales of its existing complementary medicines. Clinical outcomes, registration requirements and the timing of any subsequent development steps remain dependent on evidence and regulatory processes.

Operational Considerations

For Biome Australia (ASX:BIO), the manufacturing change introduces execution considerations around product quality, production scale-up, supplier coordination and inventory planning. Retaining European supply relationships provides an additional sourcing arrangement, although operational results will depend on actual delivery and product demand.

The company’s scientific programmes face separate uncertainties: study recruitment, trial outcomes, potential product claims and development funding. Its FY26 sales update and manufacturing agreement provide defined reporting points, while future assessments require confirmed financial disclosures rather than assumptions about clinical or commercial success.

Key Insights

Biome Australia (ASX:BIO) has reported higher H1 FY26 sales and outlined a transition towards Australian manufacturing for its Activated Probiotics range. The BMB18 programme adds a research component to the business. The distinction between reported revenue, management’s manufacturing targets and clinical evidence is important when considering the company’s disclosed 2026 activities.